Edition:
India

Allied Minds PLC (ALML.L)

ALML.L on London Stock Exchange

163.40GBp
19 Jan 2018
Change (% chg)

6.20 (+3.94%)
Prev Close
157.20
Open
161.40
Day's High
163.60
Day's Low
159.00
Volume
123,620
Avg. Vol
246,576
52-wk High
426.90
52-wk Low
114.00

Chart for

About

Allied Minds PLC (Allied Minds) is an intellectual property (IP) commercialization company. The Company is focused on venture creation within the life science and technology sectors. With extensive access to hundreds of university and federal laboratories across the United States, Allied Minds forms, funds, and operates a... (more)

Overall

Beta: 2.41
Market Cap(Mil.): £417.46
Shares Outstanding(Mil.): 237.57
Dividend: --
Yield (%): --

Financials

BRIEF-Allied Minds Announces ‍Positive Top-Line Results Of Phase 1/2 Study Of Sf0166 Eye Drops

* ‍POSITIVE TOP-LINE RESULTS OF PHASE 1/2 STUDY OF SF0166 EYE DROPS TO TREAT WET AGE-RELATED MACULAR DEGENERATION​ Further company coverage: (Bengaluru Newsroom: +91 80 6749 1136)

18 Dec 2017

Short seller Kerrisdale targets Woodford-backed Prothena

LONDON Hedge fund Kerrisdale Capital has taken a short position in drugmaker Prothena , a company backed by UK investor Neil Woodford, calling it "the next big biotech blowup".

09 Nov 2017

UPDATE 1-Short seller Kerrisdale targets Woodford-backed Prothena

* Prothena shares drop 9 percent (Updates with latest share price)

08 Nov 2017

Woodford-backed Prothena targeted by short seller Kerrisdale

LONDON, Nov 8 Hedge fund Kerrisdale Capital has taken a short position on drugmaker Prothena, a company backed by UK investor Neil Woodford, calling it "the next big biotech blowup".

08 Nov 2017

BRIEF-Allied Minds announces SciFluor SF0166 study positive top-line results

* ‍PRIMARY OUTCOME MEASURE OF SAFETY ACHIEVED WITH NO DRUG-RELATED SERIOUS ADVERSE EVENTS OBSERVED IN STUDY

28 Sep 2017

BRIEF-Allied Minds first-half loss widens​

* ‍HY LOSS FOR PERIOD: $58.2 MILLION (HY16: $52.2M), OF WHICH $44.6 MILLION ATTRIBUTABLE TO ALLIED MINDS (HY16: $41.2M)​

17 Aug 2017

Earnings vs. Estimates